Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzyga versus placebo in pediatric PANS
2020-000867-21Phase 3
- Sponsor
- Octapharma
- Start
- Aug 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pediatric acute-onset neuropsychiatric syndrome (PANS) comparing Panzyga with Placebo (2 arms). Primary endpoint: CY-BOCS score.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
pediatric acute-onset neuropsychiatric syndrome (PANS)
Beyond the preview
Go deeper on 2020-000867-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000867-21.